Literature DB >> 9347652

Levels of serum interleukin-6 and tumor necrosis factor in postsplenectomized thalassemic patients.

S Chuncharunee1, N Archararit, P Hathirat, U Udomsubpayakul, V Atichartakarn.   

Abstract

Levels of serum interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) were studied in 34 nonsplenectomized thalassemic patients (Thal/nonsplenec), 43 postsplenectomized thalassemic patients (Thal/postsplenec), 13 splenectomized non-thalassemic patients (nonThal/ postsplenec) and 18 normal control by enzyme linked immunosorbent assay method. Serum IL-6 concentration in Thal/postsplenec was significantly increased when compared with Thal/ nonsplenec and normal volunteers (3.55 +/- 2.47 pg/ml vs 2.38 +/- 2.31 pg/ml, p = 0.036 and 3.55 +/- 2.47 pg/ml vs 2.66 +/- 0.45 pg/ml, p = 0.028, respectively). This study also demonstrated that TNF-alpha value in Thal/postsplenec was drastically increased above normal control level (15.8 +/- 4.86 pg/ml vs 9.16 +/- 2.18 pg/ml, p = 0.001) and the level was statistically significantly higher than that in Thal/ nonsplenec (15.5 +/- 4.86 pg/ml vs 9.96 +/- 5.19 pg/ml, p = 0.001). There was a trend toward increasing of cytokine levels in Thal/postsplenec with higher platelet count although no correlation was observed. This study addresses the possible role of IL-6 and TNF-alpha in the pathogenesis of reactive thrombocytosis in Thal/postsplenec.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347652

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  8 in total

1.  Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.

Authors:  Gian Luca Forni; Marina Podestà; Marco Musso; Giovanna Piaggio; Khaled M Musallam; Manuela Balocco; Sarah Pozzi; Alessandra Rosa; Francesco Frassoni
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

2.  In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy.

Authors:  Vichai Atichartakarn; Pantep Angchaisuksiri; Katcharin Aryurachai; Suporn Chuncharunee; Ammarin Thakkinstian
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

3.  Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus?

Authors:  Döndü Üsküdar Cansu; Hava Üsküdar Teke; Ahmet Musmul; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2017-11-08       Impact factor: 2.631

4.  Splenic morphological changes are accompanied by altered baseline immunity in a mouse model of sickle-cell disease.

Authors:  Steven M Szczepanek; Jeffrey T McNamara; Eric R Secor; Prabitha Natarajan; Linda A Guernsey; Lauren A Miller; Enrique Ballesteros; Evan Jellison; Roger S Thrall; Biree Andemariam
Journal:  Am J Pathol       Date:  2012-09-19       Impact factor: 4.307

5.  Effect of Tumor Necrosis Factor-Alpha on Erythropoietin and Erythropoietin Receptor-Induced Erythroid Progenitor Cell Proliferation in β-Thalassemia/Hemoglobin E Patients.

Authors:  Dalina I Tanyong; Prapaporn Panichob; Wasinee Kheansaard; Suthat Fucharoen
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

Review 6.  Ineffective erythropoiesis in β -thalassemia.

Authors:  Jean-Antoine Ribeil; Jean-Benoit Arlet; Michael Dussiot; Ivan Cruz Moura; Geneviève Courtois; Olivier Hermine
Journal:  ScientificWorldJournal       Date:  2013-03-28

7.  Tumor Necrosis Factor and Splenectomy.

Authors:  İrfan Yavaşoğlu
Journal:  Turk J Haematol       Date:  2016-06-05       Impact factor: 1.831

Review 8.  Congenital Hemolytic Anemias: Is There a Role for the Immune System?

Authors:  Anna Zaninoni; Elisa Fermo; Cristina Vercellati; Anna Paola Marcello; Wilma Barcellini; Paola Bianchi
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.